A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

NCT ID: NCT06736262

Last Updated: 2025-07-20

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Clinical Phase: PHASE2
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-11-26
• Study Completion Date: 2026-12-01

Brief Summary

Phase 2, open-label, extension study to evaluate the long-term safety, clinical activity, and pharmacodynamics of briquilimab in participants previously enrolled in a Jasper sponsored CU clinical trial.

Detailed Description

This is a Phase 2, open-label, extension study to evaluate the long-term safety, clinical activity, and pharmacodynamics of briquilimab in participants previously enrolled in a Jasper sponsored CU clinical trial, specifically the BEACON (JSP-CP-011) and SPOTLIGHT (JSP CP-010) trials (referred to as "parent studies") and future CU trials sponsored by Jasper Therapeutics.

Conditions

Urticaria Chronic

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Briquilimab

Briquilimab via SQ injection

Group Type: EXPERIMENTAL

Briquilimab

Intervention Type: DRUG

No additional details needed

Interventions

Briquilimab

No additional details needed

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Provides informed written consent.

2. Previously participated in and completed an eligible Jasper-sponsored clinical trial (in the last 4 months) without any investigational product (IP)-related anaphylactic event

3. Disease specific eligibility:

1. Participants with CSU have a UAS7 of 16 or greater following the completion of at least 8 weeks of safety follow up in the parent study OR anyone who completed their parent study regardless of UAS7 score.

2. Participants with CIndU (cold contact urticaria [ColdU] or symptomatic dermographism) have a UCT of 12 or less following the completion of at least 8 weeks of safety follow up in the parent study OR anyone who completed their parent study regardless of UCT score.

4. The laboratory parameters to be within the acceptable range as follows:

1. Hemoglobin: ≥ 10 g/dL

2. Platelets: ≥ 100,000/mm3

3. Neutrophils: ≥ 1,500/mm3

4. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 3 × the upper limit of normal (ULN)

5. Serum total bilirubin < 2 × ULN, unless attributable to Gilbert's syndrome

6. Estimated creatinine clearance (eCrCl) by the Cockcroft-Gault equation (using total body weight) ≥ 30 mL/min

5. Participants willing to abstain from blood donations while being on the trial (Screening to end of trial [EOT]).

6. Male participants (who are not vasectomized) who are heterosexually active must use highly effective contraceptive methods and must abstain from sperm donation during the trial and for at least 8 months after the last dose of briquilimab. A male participant is considered vasectomized if he had a vasectomy at least 4 months prior to Screening and if he has received post-surgical medical assessment of the surgical success of the vasectomy

7. Female participants of childbearing potential who are heterosexually active (defined in Section 5.2.1.1) must use highly effective contraceptive methods (Section 5.2.1) during the trial and for at least 90 days after the last dose of briquilimab. Female participants of non-childbearing potential must be surgically sterile (i.e., had undergone complete hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or be in a menopausal state (at least 1 year without menses).

Exclusion Criteria

1. Participated in or currently participating in an interventional clinical trial investigating an experimental therapy following cessation of participation in a Jasper-sponsored CU trial.

2. Other active diseases with possible symptoms of urticaria, wheals or angioedema, including urticarial vasculitis, erythema multiforme, systemic or cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema (e.g., due to C1 inhibitor deficiency)

3. Women who are pregnant or nursing or intend to become pregnant during the course of the trial

4. Any known contraindications or hypersensitivity to any component of briquilimab, drugs of similar chemical classes (i.e., to murine, chimeric or human antibodies) or antihistamines or leukotrienes. Those who have previously experienced an IP-related anaphylactic event, IP-related SAE, or IP-related AE that led to treatment discontinuation in a prior Jasper-sponsored urticaria clinical trial, which in the opinion of the Investigator or medical monitor, may indicate that continued treatment could present an unreasonable risk to the participant are also excluded.

5. Any other acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or briquilimab administration or could interfere with the interpretation of trial results and, in the judgment of the Investigator, would make the participant inappropriate for entry into the trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jasper Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Jasper Therapeutics

Locations

Investigative Site 118

Birmingham, Alabama, United States

Investigative Site 108

Little Rock, Arkansas, United States

Investigative Site 105

San Diego, California, United States

Investigative Site 116

Tampa, Florida, United States

Investigative Site 109

Boise, Idaho, United States

Investigative Site 124

Normal, Illinois, United States

Investigative Site 110

Indianapolis, Indiana, United States

Investigative Site 123

Lafayette, Louisiana, United States

Investigative Site 101

Baltimore, Maryland, United States

Investigative Site 121

White Marsh, Maryland, United States

Investigative Site 103

Cincinnati, Ohio, United States

Investigative Site 111

Murray, Utah, United States

Investigative Site 115

Seattle, Washington, United States

Investigative Site 210

München, Bavaria, Germany

Investigative Site 202

Marburg, Hesse, Germany

Investigative Site 204

Münster, North Rhine-Westphalia, Germany

Investigative Site 209

Dresden, Saxony, Germany

Investigative Site 206

Lübeck, Schleswig-Holstein, Germany

Investigative Site 201

Berlin, State of Berlin, Germany

Countries

United States; Germany

Other Identifiers

2024-517830-17-00

Identifier Type: CTIS

Identifier Source: secondary_id

JSP-CP-014

Identifier Type: -

Identifier Source: org_study_id